IDH2 and central nervous system cancer: WHO 2021 overcomes some of the limitations of sampling error in IDH-wildtype gliomas through the addition of molecular criteria [2], but this is less the case for IDH-mutant gliomas; thus, imaging features continue to provide prognostic value in the molecular era.